Under the terms of the agreement, Solvay Pharmaceuticals would make an upfront payment, make future milestone payments, and pay royalties based upon product sales to Lipocine. Solvay Pharmaceuticals will also fund Lipocine development expenses associated with this program. Solvay Pharmaceuticals plans to initiate a development program to further study the investigational product as an oral treatment for male hypogonadism also known as low testosterone (low T).
Deal Type Partnership Sub-Category Development,Commercialization,Acquisition of Rights,Sales Deal Status Announced: 2009-05-19
Deal Participants
Partner 1 (Company) Solvay Pharmaceuticals, Inc. Partner 2 (Company) Solvay S.A. Partner 3 (Company) Lipocine, Inc.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index